High grade serous (HGS) cancer of the ovary (OC) is a lethal malignancy with advanced stage disease remaining incurable. HGS OC is sensitive to platinum based chemotherapy with complete responses being frequent, but relapses are inevitable, with resistance invariably emerging. Deeper understanding of the pathogenesis of HGS OC with new sequencing techniques shows that aberrations in the BRCA pathway may play a major role. Changes in the homologous recombination pathway and DNA repair may play a role in platinum resistance. This review article describes various approaches that have been studied in the management of chemotherapy resistance in HGS OC including Poly ADPribose polymerase (PARP) inhibition, Wee1 inhibition, epigenetic agents, immunotherapy and angiogenesis targeting agents.
Keywords: Chemotherapy, high grade serous, ovarian, resistance.
Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) Editorial (Thematic Issue The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: The Operations Behind a Herculean Task)
Reviews on Recent Clinical Trials Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours
Current Signal Transduction Therapy In Vitro and In Vivo Biodistribution of ZRS1, a Stabilized Type I N-Acetoxymethyl Carbamate-Containing Combi-Molecule
Drug Metabolism Letters Effects of CAP-regimen Chemotherapy on Blood Redox Status in Patients with Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry Psychological Sequelae of Ovarian Cancer Screening and Genetic Testing for Ovarian Cancer Susceptibility
Current Women`s Health Reviews Exome Sequencing of Ovarian Cancer Patients to Identify Variants Predictive of Sensitivity to Platinum-based Chemotherapy
Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Current Drug Targets Tumor Marker Detection by Aptamer-Functionalized Graphene Oxide
Current Organic Chemistry Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance
Current Pharmaceutical Design HGF/MET Signaling in Ovarian Cancer
Current Molecular Medicine Current Status of Primary Cytoreductive Surgery for the Treatment of Advanced Epithelial Ovarian Cancer
Current Cancer Therapy Reviews The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer
Recent Patents on Biotechnology Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance
Current Protein & Peptide Science Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors
Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) Gene Directed Enzyme Prodrug Therapy for Ovarian Cancer: Could GDEPT Become a Promising Treatment Against Ovarian Cancer?
Anti-Cancer Agents in Medicinal Chemistry New Ultrasound-Based Technologies for Predicting Ovarian Cancer in Adnexal Masses
Current Women`s Health Reviews Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy
Current Cancer Drug Targets